SmithKline Memric not associated with liver toxicity, researcher tells Alzheimer's Association.
Executive Summary
SMITHKLINE MEMRIC DOES NOT HAVE LIVER TOXICITY OF TACRINE, RESEARCHER Steven DeKosky, MD, University of Pittsburgh Medical Center, told an Alzheimer's Association meeting in New York City Feb. 5. DeKosky reported that Memric, formerly known as SB 202026, is in Phase III studies. Memric, like Warner-Lambert/Roussel Uclaf's milameline and Lilly's xanomeline, is an M1 receptor agonist, DeKosky observed. "None of these" muscarinic agonists "have the liver toxicity of tacrine" (Warner-Lambert's reversible cholinesterase inhibitor Cognex), he reported.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth